
Ruth M Risueño

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9119775/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT	/Overlack 1	0 T <u>f 50</u> 742 T 1,497
2	Direct conversion of human fibroblasts to multilineage blood progenitors. Nature, 2010, 468, 521-526.	27.8	652
3	Identification of Drugs IncludingÂa DopamineÂReceptor Antagonist that Selectively Target Cancer Stem Cells. Cell, 2012, 149, 1284-1297.	28.9	420
4	Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. Journal of Experimental Medicine, 2005, 202, 493-503.	8.5	288
5	Cooperativity Between T Cell Receptor Complexes Revealed by Conformational Mutants of CD3É›. Science Signaling, 2009, 2, ra43.	3.6	90
6	The lincRNA <i>HOTAIRM1</i> , located in the <i>HOXA</i> genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget, 2015, 6, 31613-31627.	1.8	78
7	Ligand-induced conformational change in the T-cell receptor associated with productive immune synapses. Blood, 2005, 106, 601-608.	1.4	74
8	A conformation- and avidity-based proofreading mechanism for the TCR–CD3 complex. Trends in Immunology, 2006, 27, 176-182.	6.8	65
9	Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Current Opinion in Hematology, 2008, 15, 319-325.	2.5	49
10	Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology, 2017, 24, 833-844.e9.	5.2	38
11	A conformational change senses the strength of T cell receptor-ligand interaction during thymic selection. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9625-9630.	7.1	37
12	Inability of Human Induced Pluripotent Stem Cell-Hematopoietic Derivatives to Downregulate MicroRNAs In Vivo Reveals a Block in Xenograft Hematopoietic Regeneration. Stem Cells, 2012, 30, 131-139.	3.2	33
13	T Cell Receptor Engagement Triggers Its CD3ε and CD3ζ Subunits to Adopt a Compact, Locked Conformation. PLoS ONE, 2008, 3, e1747.	2.5	30
14	Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood, 2011, 117, 7112-7120.	1.4	21
15	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. Leukemia, 2017, 31, 2288-2302.	7.2	20
16	XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget, 2014, 5, 4337-4346.	1.8	20
17	Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. EBioMedicine, 2019, 47, 221-234.	6.1	19
18	Repositioning of bromocriptine for treatment of acute myeloid leukemia. Journal of Translational Medicine, 2016, 14, 261.	4.4	18

Ruth M Risueñо

#	Article	IF	CITATIONS
19	The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Clinical and Experimental Immunology, 2007, 150, 375-385.	2.6	17
20	Differential antibody binding to the surface ÂÂTCR{middle dot}CD3 complex of CD4+ and CD8+ T lymphocytes is conserved in mammals and associated with differential glycosylation. International Immunology, 2008, 20, 1247-1258.	4.0	16
21	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. Leukemia Research, 2014, 38, 874-881.	0.8	16
22	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. Oncotarget, 2016, 7, 23239-23250.	1.8	13
23	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Scientific Reports, 2018, 8, 13883.	3.3	11
24	Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes. Scientific Reports, 2020, 10, 18927.	3.3	6
25	Natural killer cells efficiently target multiple myeloma clonogenic tumor cells. Cancer Immunology, Immunotherapy, 2021, 70, 2911-2924.	4.2	6
26	Conformational Model. Advances in Experimental Medicine and Biology, 2008, 640, 103-112.	1.6	6
27	Brief Report: Ectopic Expression of Nup98-HoxA10 Augments Erythroid Differentiation of Human Embryonic Stem Cells. Stem Cells, 2011, 29, 736-741.	3.2	4
28	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell International, 2015, 15, 122.	4.1	4
29	Lysosome-mediated chemoresistance in acute myeloid leukemia. Cancer Drug Resistance (Alhambra,) Tj ETQq1	1 0.78431 2.1	4 rgBT /Overle
30	Targeting LSCs: powering an old tool. Blood, 2008, 111, 5423-5424.	1.4	1
31	Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity. Journal of Cellular and Molecular Medicine, 2020, 24, 13536-13541.	3.6	1
32	New Therapeutic Approaches for Acute Myeloid Leukaemia. European Medical Journal (Chelmsford,) Tj ETQqO C) 0 rgBT /O	verlock 10 Tf 5
33	G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S189-S190.	0.4	Ο
34	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. Blood, 2013, 122, 1339-1339.	1.4	0
35	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577.	1.4	Ο
36	Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma. Blood, 2014, 124, 3467-3467.	1.4	0

#	Article	IF	CITATIONS
37	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood, 2014, 124, 1003-1003.	1.4	Ο
38	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2511-2511.	1.4	0
39	Biological and Therapeutic Implications of Cancer Stem Cells. , 2016, , 63-101.		Ο